<div id="userFeedbackContainer">
					<img height="11" width="11" src="/images/social-media/icon_comments.gif"/>
	<a href="" id="numComments" onclick="jQuery.scrollTo('#commentsInput', 500);return false;" title="Comment on this article" style="cursor:pointer;">
		{var numComments = 0;}
		{if ResponseBatch.Responses.length != 0}
			{var numComments = ResponseBatch.Responses[0].Article.Comments.NumberOfComments;}
		{/if}
		${numComments}
		 Comment{if numComments != 1}s{/if}
		{if numComments == 0}
			 - Comment First!
		{/if}
	</a>
		
	{var numRatings = 0;}
		
	{if ResponseBatch.Responses.length != 0}
		{var numRatings = ResponseBatch.Responses[0].Article.Ratings.NumberOfRatings;}
		{var rating = ResponseBatch.Responses[0].Article.Ratings;}
		{var avgRating = rating.AverageRating;}
	{/if}
	{if numRatings != 0}
		
			{var numStars = [0,1,2,3,4]}
			{for star in numStars}
				{var fileName = "star-hover.jpg"}
				{if star+1 > avgRating}
					{var fileName = "star-unselected.jpg"}
				{/if}
				<img src='/images/social-media/${fileName}'/>
			{/for}
		
	{/if}
	<a href="" id="numRatings" onclick="jQuery.scrollTo('#rating', 500);return false;" title="Rate this article" style="cursor:pointer;">
		${numRatings}
		 Rating{if numRatings != 1}s{/if}
		{if numRatings == 0}
			 - Rate First!
		{/if}
	</a>
			</div>

Merck set to close US$41-billion purchase of Schering-Plough

From The Associated Press, November 3, 2009 - 12:49 a.m.

Merck set to close US$41-billion purchase of Schering-Plough

By The Associated Press

Article Tools

TRENTON, N.J. - Merck&Co. is set to complete its US$41-billion acquisition of Schering-Plough Corp. later Tuesday, creating the world's second-largest drugmaker, behind Pfizer Inc.

The companies expect the deal will close after the end of market trading Tuesday.

The completion comes after the U.S. Federal Trade Commission approved the deal Thursday. Regulators in Europe and elsewhere, and shareholders of both companies, have already approved it.

The two companies have been jointly selling the cholesterol drugs Vytorin and Zetia for years.

The deal adds allergy drugs Nasonex and Clarinex to Merck's Singulair and its diabetes pill Januvia. It also gives Merck animal and consumer health products, and a promising biotech division.